These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33070999)

  • 1. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
    Gurwith M; Condit RC; Excler JL; Robertson JS; Kim D; Fast PE; Drew S; Wood D; Klug B; Whelan M; Mallett Moore T; Khuri-Bulos N; Smith ER; Chen RT; Kochhar S;
    Vaccine; 2020 Nov; 38(49):7702-7707. PubMed ID: 33070999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
    Condit RC; Kim D; Robertson JS; Excler JL; Gurwith M; Monath TP; Pavlakis G; Fast PE; Smith J; Smith ER; Chen RT; Kochhar S;
    Vaccine; 2020 Nov; 38(49):7708-7715. PubMed ID: 32907759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
    Kochhar S; Kim D; Excler JL; Condit RC; Robertson JS; Drew S; Whelan M; Wood D; Fast PE; Gurwith M; Klug B; Khuri-Bulos N; Smith ER; Chen RT;
    Vaccine; 2020 Jul; 38(35):5734-5739. PubMed ID: 32653276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
    Kim D; Robertson JS; Excler JL; Condit RC; Fast PE; Gurwith M; Pavlakis G; Monath TP; Smith J; Wood D; Smith ER; Chen RT; Kochhar S;
    Vaccine; 2020 Jul; 38(34):5556-5561. PubMed ID: 32571717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
    Kochhar S; Excler JL; Kim D; Robertson JS; Fast PE; Condit RC; Drew S; Wood D; Gurwith M; Klug B; Whelan M; Khuri-Bulos N; Mallett Moore T; Smith ER; Chen RT;
    Vaccine; 2020 Sep; 38(39):6184-6189. PubMed ID: 32747214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.
    Monath TP; Seligman SJ; Robertson JS; Guy B; Hayes EB; Condit RC; Excler JL; Mac LM; Carbery B; Chen RT;
    Vaccine; 2015 Jan; 33(1):62-72. PubMed ID: 25446819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.
    Clarke DK; Hendry RM; Singh V; Rose JK; Seligman SJ; Klug B; Kochhar S; Mac LM; Carbery B; Chen RT;
    Vaccine; 2016 Dec; 34(51):6597-6609. PubMed ID: 27395563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
    Eldridge JH; Egan MA; Matassov D; Hamm S; Hermida L; Chen T; Tremblay M; Sciotto-Brown S; Xu R; Dimitrov A; Smith ER; Gurwith M; Chen RT;
    Vaccine; 2021 Sep; 39(38):5436-5441. PubMed ID: 34373117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG).
    Chen RT; Kochhar S; Condit R
    Vaccine; 2021 May; 39(22):3050-3052. PubMed ID: 33168344
    [No Abstract]   [Full Text] [Related]  

  • 10. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).
    Chen RT; Carbery B; Mac L; Berns KI; Chapman L; Condit RC; Excler JL; Gurwith M; Hendry M; Khan AS; Khuri-Bulos N; Klug B; Robertson JS; Seligman SJ; Sheets R; Williamson AL;
    Vaccine; 2015 Jan; 33(1):73-5. PubMed ID: 25305565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
    Custers J; Kim D; Leyssen M; Gurwith M; Tomaka F; Robertson J; Heijnen E; Condit R; Shukarev G; Heerwegh D; van Heesbeen R; Schuitemaker H; Douoguih M; Evans E; Smith ER; Chen RT;
    Vaccine; 2021 May; 39(22):3081-3101. PubMed ID: 33676782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
    Hernandez LM; Sumathy K; Sahastrabuddhe S; Excler JL; Kochhar S; Smith ER; Gurwith M; Chen RT;
    Vaccine; 2022 Aug; 40(35):5263-5274. PubMed ID: 35715351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
    Leav B; Straus W; White P; Leav A; Gaines T; Maggiacomo G; Kim D; Smith ER; Gurwith M; Chen RT;
    Vaccine; 2022 Aug; 40(35):5275-5293. PubMed ID: 35753841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.
    Condit RC; Williamson AL; Sheets R; Seligman SJ; Monath TP; Excler JL; Gurwith M; Bok K; Robertson JS; Kim D; Michael Hendry R; Singh V; Mac LM; Chen RT;
    Vaccine; 2016 Dec; 34(51):6610-6616. PubMed ID: 27346303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
    Perez EE; Bokszczanin A; McDonald-McGinn D; Zackai EH; Sullivan KE
    Pediatrics; 2003 Oct; 112(4):e325. PubMed ID: 14523220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
    Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
    Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Possible Path towards Rapid Development of Live-Attenuated SARS-CoV-2 Vaccines: Plunging into the Natural Pool.
    Todorov G; Uversky VN
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33066343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinia virus recombinant vaccines for rinderpest.
    Yilma T
    Dev Biol Stand; 1995; 84():201-8. PubMed ID: 7796955
    [No Abstract]   [Full Text] [Related]  

  • 20. Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.
    Klug B; Robertson JS; Condit RC; Seligman SJ; Laderoute MP; Sheets R; Williamson AL; Gurwith M; Kochhar S; Chapman L; Carbery B; Mac LM; Chen RT;
    Vaccine; 2016 Dec; 34(51):6617-6625. PubMed ID: 27317264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.